Epizyme Scientists Detail Epigenetic Approaches to Cancer Therapy in Drug Discovery Today: Therapeutic Strategies and Current Opinion in Chemical Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme’s scientific leadership in the area of epigenetics. The article titled “Targeting epigenetic enzymes for drug discovery” appeared in the July 2010 issue of Current Opinion in Chemical Biology, and the article titled “Epigenetic approaches to cancer therapy” was published in the Summer 2010 issue of Drug Discovery Today: Therapeutic Strategies.